Kestra Medical Technologies' (KMTS) "Sell (D)" Rating Reaffirmed at Weiss Ratings

Key Points

• Weiss Ratings has reaffirmed a "sell (D)" rating for Kestra Medical Technologies (KMTS), indicating ongoing concerns regarding the stock's performance.
• Wells Fargo & Company reduced its price target for KMTS from $28.00 to $27.00 but maintains an "overweight" rating, while a recent analysis from Wall Street Zen downgraded the stock to "sell."
• Institutional investors have shown significant interest, with multiple firms, including Brown Advisory Inc. and Federated Hermes Inc., acquiring substantial stakes in the company recently.

Kestra Medical Technologies (NASDAQ:KMTS - Get Free Report)'s stock had its "sell (d)" rating restated by Weiss Ratings in a report released on Wednesday,Weiss Ratings reports.

KMTS has been the topic of several other research reports. Wells Fargo & Company reduced their price target on shares of Kestra Medical Technologies from $28.00 to $27.00 and set an "overweight" rating on the stock in a research report on Thursday, July 17th. Wall Street Zen cut Kestra Medical Technologies from a "hold" rating to a "sell" rating in a research note on Sunday, September 28th. Five equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $27.33.

Kestra Medical Technologies Stock Down 1.6%

Kestra Medical Technologies stock opened at $24.00 on Wednesday. The company has a debt-to-equity ratio of 0.23, a quick ratio of 6.84 and a current ratio of 6.84. The company has a 50-day moving average price of $19.43 and a 200 day moving average price of $20.21. Kestra Medical Technologies has a 12-month low of $13.25 and a 12-month high of $27.71.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of KMTS. Brown Advisory Inc. purchased a new stake in shares of Kestra Medical Technologies in the 1st quarter valued at $13,716,000. Caas Capital Management LP acquired a new position in Kestra Medical Technologies in the 1st quarter valued at about $1,470,000. Jennison Associates LLC purchased a new stake in Kestra Medical Technologies during the first quarter worth about $1,869,000. TD Asset Management Inc acquired a new stake in shares of Kestra Medical Technologies during the first quarter worth about $2,306,000. Finally, Federated Hermes Inc. purchased a new position in shares of Kestra Medical Technologies in the first quarter valued at approximately $9,968,000.

Kestra Medical Technologies Company Profile

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.